Stereotaxis Inc.

STXS Healthcare Medical Instruments & Supplies

Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024.

Revenue
−12.8%
EPS
0.00%
Free cash flow
+0.45%

Quarter to June 2026, against a year earlier

1.11 0.06 +5.71%
Market cap
$105.2M
P/E
0.0×
Fwd P/E
−4.2×
Dividend yield
—
F-score
5/9
Altman Z
−12.40
Beneish M
−1.95
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 5 5 5
ROE
(291.61%) (234.28%) (266.26%) (344.36%)
ROA
(51.60%) (46.30%) (46.02%) (48.76%)
ROIC
(1,464.62%) (260.75%) (278.05%) (203.58%)
Return on Tangible Assets
(263.57%) (157.94%) (144.36%) (167.63%)
Average Days of Receivables
64.73 114.57 112.54 168.31
Free Cash Flow per Share
(0.09) (0.15) (0.16) (0.15)
Free Cash Flow
(8.48) (13.78) (15.52) (15.50)
Other line items

Show all line items

Columns are period end dates